Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 9/20 | 0.51 |
| ▸ | FAAH | O00519 | 3/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7770681 | 1.00 | EPHX1 (0.58) | EPHX1ACHEFAAHNAAANPC1 | |
| SCHEMBL7770680 | 1.00 | EPHX1 (0.58) | EPHX1ACHEFAAHNAAANPC1 | |
| SCHEMBL16124605 | 1.00 | EPHX1 (0.58) | EPHX1ACHEFAAHNAAANPC1 | |
| SCHEMBL2494231 | 0.98 | EPHX1 (0.55) | EPHX1ACHEFAAHNAAANPC1 | |
| SCHEMBL2494230 | 0.98 | EPHX1 (0.55) | EPHX1ACHEFAAHNAAANPC1 | |
| SCHEMBL476725 | 0.93 | EPHX1 (0.47) | EPHX1ACHEFAAHNPC1RAB9A | |
| SCHEMBL459574 | 0.93 | EPHX1 (0.47) | EPHX1ACHEFAAHNPC1RAB9A | |
| SCHEMBL459573 | 0.93 | EPHX1 (0.47) | EPHX1ACHEFAAHNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL10476064 | 0.91 | EPHX1 (0.46) | EPHX1ACHEFAAHNPC1RAB9A | |
| SCHEMBL7616231 | 0.87 | MME (0.42) | EPHX1ACHEFAAHNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024043313-A1 | REVERSIBLE THERMOCHROMIC COMPOSITION, MICROENCAPSULATED PIGMENT USING SAID REVERSIBLE THERMOCHROMIC COMPOSITION, WRITING TOOL, AND TOY | 三菱ケミカル株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | EPHX1 476/4885ACHE 394/4885FAAH 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.